Main Article Content
Coronavirus disease 2019 (COVID-19) has spread throughout China and gained world-wide attention as a result of acute respiratory illness due to a novel coronavirus (SARS-CoV-2), traditionally known as COVID-19. On 30 January 2020, the World Health Organization (WHO) officially announced the outbreak of COVID-19 a public health emergency of international concern.A third introduction of a highly pathogenic and large-scale coronavirus disease in humans was the SARS-CoV-2 outbreak as a result of a severe acute respiratory syndrome coronavirus (SARS-CoV) in 2003 and the Middle East respiratory syndrome coronavirus (MERS-CoV) in 2012. Medical signs of COVID-19 patients include fever, cough, exhaustion and a limited number of patients with signs of gastrointestinal infection. Elderly and people with underlying diseases are susceptible to infection and prone to adverse results that could be associated with acute respiratory distress syndrome. There are currently few specific antiviral approaches available but many effective antiviral and repurposed drug candidates are under urgent investigation. The aim of this review was to summarize the recent medical advancement of COVID-19's epidemiology, transmission, and clinical characteristics, and discussed current treatment and scientific developments to fight the novel coronavirus outbreak.
Accessed: 31 December 2019.
WHO. Novel coronavirus – China. Geneva, Switzerland: World Health Organization; 2020.
(Accessed: 12 January 2020)
Wang C, Horby PW, Hayden FG, Gao GF. A novel coronavirus outbreak of global health concern. The Lancet. 2020; 395(10223):470-3.
Hui DS, I Azhar E, Madani TA, Ntoumi F, Kock R, Dar O, et al. The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health—The latest 2019 novel coronavirus outbreak in Wuhan, China. International Journal of Infectious Diseases. 2020;91:264-6.
Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. China Novel Coronavirus Investigating and Research Team. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020; 382(8):727-33.
Cheng VC, Lau SK, Woo PC, Yuen KY. Severe acute respiratory syndrome coronavirus as an agent of emerging and reemerging infection. Clinical Microbiology Reviews. 2007;20(4):660-94.
Chan JF-W, Kok K-H, Zhu Z, Chu H, To KK-W, Yuan S, et al. Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan. Emerging Microbes & Infections. 2020;9(1):221-36.
Tan W, Zhao X, Ma X, Wang W, Niu P, Xu W, et al. A novel coronavirus genome identified in a cluster of pneumonia cases—Wuhan, China 2019− 2020. China CDC Weekly. 2020;2(4):61-2.
Paules CI, Marston HD, Fauci AS. Coronavirus infections—more than just the common cold. Jama. 2020;323(8):707-8.
Chowell G, Abdirizak F, Lee S, Lee J, Jung E, Nishiura H, et al. Transmission characteristics of MERS and SARS in the healthcare setting: a comparative study. BMC medicine. 2015;13(1): 210.
HuangCL W. Clinicalfea⁃ tures of patients infected with 2019 novel coronavirus in Wuhan. China. 2020;395(10223):497-506.
Chan JF-W, Yuan S, Kok K-H, To KK-W, Chu H, Yang J, et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: A study of a family cluster. The Lancet. 2020;395(10223): 514-23.
Tsang KW, Ho PL, Ooi GC, Yee WK, Wang T, Chan-Yeung M, et al. A cluster of cases of severe acute respiratory syndrome in Hong Kong. New England Journal of Medicine. 2003;348(20):1977-85.
Peiris J, Lai S, Poon L, Guan Y, Yam L, Lim W, et al. Coronavirus as a possible cause of severe acute respiratory syndrome. The Lancet. 2003;361(9366): 1319-25.
Siu A, Wong YR. Economic impact of SARS: The case of Hong Kong. Asian Economic Papers. 2004;3(1):62-83.
WHO. SARS (Severe Acute Respiratory Syndrome)
Accessed: 7 April 2020.
Peiris JS, Yuen KY, Osterhaus AD, Stöhr K. The severe acute respiratory syndrome. New England Journal of Medicine. 2003; 349(25):2431-41.
Scales DC, Green K, Chan AK, Poutanen SM, Foster D, Nowak K, et al. Illness in intensive care staff after brief exposure to severe acute respiratory syndrome. Emerging Infectious Diseases. 2003; 9(10):1205.
Donnelly CA, Ghani AC, Leung GM, Hedley AJ, Fraser C, Riley S, et al. Epidemiological determinants of spread of causal agent of severe acute respiratory syndrome in Hong Kong. The Lancet. 2003;361(9371):1761-6.
WHO. Middle East respiratory syndrome coronavirus (MERS-CoV); 2020.
Accessed: 27 March 2020.
Tesini BBL. Coronaviruses and Acute Respiratory Syndromes (COVID-19, MERS, and SARS),MD, University of Rochester School of Medicine and Dentistry; 2020.
(Accessed: 27 March 2020)
World Health Organization Novel Coronavirus—Japan (ex-China); 2010.
(Accessed: 29 March 2020)
Ji W, Wang W, Zhao X, Zai J, Li X. Homologous recombination within the spike glycoprotein of the newly identified coronavirus may boost cross-species transmission from snake to human. J Med Virol; 2020.
Robertson D. JX. nCoV’s Relationship to Bat Coronaviruses and Recombination Signals No Snakes; 2020.
(Accessed 28 March 2020)
Kan B, Wang M, Jing H, Xu H, Jiang X, Yan M, et al. Molecular evolution analysis and geographic investigation of severe acute respiratory syndrome coronavirus-like virus in palm civets at an animal market and on farms. Journal of Virology. 2005;79(18):11892-900.
Lau SK, Woo PC, Li KS, Huang Y, Tsoi H-W, Wong BH, et al. Severe acute respiratory syndrome coronavirus-like virus in Chinese horseshoe bats. Proceedings of the National Academy of Sciences. 2005;102(39):14040-5.
Menachery VD, Yount Jr BL, Debbink K, Agnihothram S, Gralinski LE, Plante JA, et al. A SARS-like cluster of circulating bat coronaviruses shows potential for human emergence. Nature medicine. 2015;21(12): 1508.
Menachery VD, Yount BL, Sims AC, Debbink K, Agnihothram SS, Gralinski LE, et al. SARS-like WIV1-CoV poised for human emergence. Proceedings of the National Academy of Sciences. 2016; 113(11):3048-53.
Wang N, Li S-Y, Yang X-L, Huang H-M, Zhang Y-J, Guo H, et al. Serological evidence of bat SARS-related coronavirus infection in humans, China. Virologica Sinica. 2018;33(1):104-7.
Anthony SJ, Gilardi K, Menachery V, Goldstein T, Ssebide B, Mbabazi R, et al. Further evidence for bats as the evolutionary source of Middle East respiratory syndrome coronavirus. MBio. 2017;8(2):e00373-17.
Quan P-L, Firth C, Street C, Henriquez JA, Petrosov A, Tashmukhamedova A, et al. Identification of a severe acute respiratory syndrome coronavirus-like virus in a leaf-nosed bat in Nigeria. MBio. 2010;1(4): e00208-10.
Azhar EI, El-Kafrawy SA, Farraj SA, Hassan AM, Al-Saeed MS, Hashem AM, et al. Evidence for camel-to-human trans-mission of MERS coronavirus. New England Journal of Medicine. 2014; 370(26):2499-505.
WHO. Coronavirus disease (COVID-19); 2020.
(Accessed: 9 April 2020)
National Health Commission of People’s Republic of China. Prevent guideline of 2019-nCoV; 2020.
(Accessed: 28 March 2020)
CDC. 2019 Novel coronavirus, Wuhan, China; 2020.
(Accessed: 28 March 2020)
Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y, et al. Early transmission dynamics in Wuhan, China, of novel coronavirus–infected pneumonia. New England Journal of Medicine; 2020.
WHO. Novel Coronavirus–China; 2020. (Accessed: 28 March 2020)
Liu T, Hu J, Xiao J, He G, Kang M, Rong Z, et al. Time-varying transmission dynamics of Novel Coronavirus Pneumonia in China. bioRxiv; 2020.
Gralinski LE, Menachery VD. Return of the Coronavirus: 2019-nCoV. Viruses. 2020; 12(2):135.
National Health Commission of People’s Republic of China. Pneumonia diagnosis and treatment of 2019-nCoV infection from Chinese NHC and CDC; 2020.
(Accessed: 27 March 2020)
Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The Lancet. 2020; 395(10223):497-506.
Li T, Wei C, Li W, Hongwei F, Shi J. Beijing Union Medical College Hospital on pneumonia of novel coronavirus infection diagnosis and treatment proposal. Med J Peking Union Med Coll Hosp; 2020.
Liu Y, Li J, Feng Y. Critical care response to a hospital outbreak of the 2019-nCoV infection in Shenzhen, China. BioMed Central; 2020.
Lai CC, Shih TP, Ko WC, Tang HJ, Hsueh PR. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and corona virus disease-2019 (COVID-19): the epidemic and the challenges. International Journal of Antimicrobial Agents. 2020;105924.
Gao J, Tian Z, Yang X. Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Bioscience trends; 2020.
Luo H, Tang Q-l, Shang Y-x, Liang S-b, Yang M, Robinson N, et al. Can Chinese medicine be used for prevention of corona virus disease 2019 (COVID-19)? A review of historical classics, research evidence and current prevention programs. Chinese Journal of Integrative Medicine. 2020;1-8.
Rosa SGV, Santos WC. Clinical trials on drug repositioning for COVID-19 treatment. Revista Panamericana de Salud Pública. 2020;44.
Cascella M, Rajnik M, Cuomo A, Dulebohn SC, Di Napoli R. Features, Evaluation and TreatmentCoronavirus (COVID-19). Stat Pearls [Internet] StatPearls Publishing; 2020.